


a.) Amendment to the Claims:

1. (Original) A pharmaceutical composition which comprises
 - (a) (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7- dihydro-1H-purine-2,6-dione represented by the formula (I):



or a pharmaceutically acceptable salt thereof, and

- (b) an antidepressant drug.

Claim 2 (Cancelled).

3. (Currently Amended) The pharmaceutical composition according to ~~claim 1 or 2~~ claim 1, wherein the antidepressant drug is a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor or a serotonin 2 (5-HT₂) antagonist.

4. (Currently Amended) The pharmaceutical composition according to
~~claim 1 or 2~~ claim 1, wherein the antidepressant drug is a tricyclic antidepressant.

5. (Original) The pharmaceutical composition according to claim 4,
wherein the tricyclic antidepressant is imipramine hydrochloride, clomipramine
hydrochloride, amitriptyline hydrochloride, nortriptyline hydrochloride, amoxapine,
trimipramine maleate, lofepramine, lofepramine hydrochloride, dosulepin hydrochloride,
protriptyline, doxepin or desipramine hydrochloride.

6. (Currently Amended) The pharmaceutical composition according to
~~claim 1 or 2~~ claim 1, wherein the antidepressant drug is a tetracyclic antidepressant.

7. (Original) The pharmaceutical composition according to claim 6,
wherein the tetracyclic antidepressant is maprotiline hydrochloride, mianserin
hydrochloride or setiptiline maleate.

8. (Currently Amended) The pharmaceutical composition according to
~~claim 1 or 2~~ claim 1, wherein the antidepressant drug is a selective serotonin reuptake
inhibitor.

9. (Original) The pharmaceutical composition according to claim 8, wherein the selective serotonin reuptake inhibitor is fluoxetine hydrochloride, sertraline hydrochloride, paroxetine hydrochloride, paroxetine hydrochloride hydrate, citalopram hydrobromide, fluvoxamine maleate, trazodone hydrochloride or nefazodone hydrochloride.

10. (Currently Amended) The pharmaceutical composition according to ~~claim 1 or 2~~ claim 1, wherein the antidepressant drug is a selective noradrenalin reuptake inhibitor.

11. (Original) The pharmaceutical composition according to claim 10, wherein the selective noradrenalin reuptake inhibitor is reboxetine mesylate, mirtazapine, maprotiline hydrochloride, nortriptyline hydrochloride, amoxapine, bupropion or bupropion hydrochloride.

12. (Currently Amended) The pharmaceutical composition according to ~~claim 1 or 2~~ claim 1, wherein the antidepressant drug is a serotonin-noradrenalin reuptake inhibitor.

13. (Original) The pharmaceutical composition according to claim 12, wherein the serotonin-noradrenalin reuptake inhibitor is milnacipran hydrochloride, venlafaxine hydrochloride or duloxetine hydrochloride.

14. (Currently Amended) The pharmaceutical composition according to ~~claim 1 or 2~~ claim 1, wherein the antidepressant drug is a dopamine reuptake inhibitor.

15. (Original) The pharmaceutical composition according to claim 14, wherein the dopamine reuptake inhibitor is venlafaxine hydrochloride.


16. (Currently Amended) The pharmaceutical composition according to claim 1 or 2 claim 1, wherein the antidepressant drug is a monoamine oxidase inhibitor.

17. (Original) The pharmaceutical composition according to claim 16, wherein the monoamine oxidase inhibitor is selegiline hydrochloride, safinamide mesylate or moclobemide.

18. (Currently Amended) The pharmaceutical composition according to ~~claim 1 or 2~~ claim 1, wherein the antidepressant drug is a 5-HT₂ antagonist.

19. (Original) The pharmaceutical composition according to claim 18, wherein the 5-HT₂ antagonist is mirtazapine, trazodone hydrochloride or nefazodone hydrochloride.

20. (Currently Amended) A ~~therapeutic agent for depression~~ pharmaceutical kit which comprises (a) (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione represented by the formula (I):



or a pharmaceutically acceptable salt thereof and

(b) an antidepressant drug

for administering simultaneously or separately at a time interval.

21. (Currently Amended) ~~The therapeutic agent for depression kit~~ according claim 20, wherein the antidepressant drug is a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin

reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor or a 5-HT₂ antagonist.

22. (Currently Amended) The ~~therapeutic agent for depression~~ kit according to claim 20, wherein the antidepressant drug is a tricyclic antidepressant.

23. The ~~therapeutic agent for depression~~ kit according to claim 22, wherein the tricyclic antidepressant is imipramine hydrochloride, clomipramine hydrochloride, amitriptyline hydrochloride, nortriptyline hydrochloride, amoxapine, trimipramine maleate, lofepramine, lofepramine hydrochloride, dosulepin hydrochloride, protriptyline, doxepin or desipramine hydrochloride.

24. (Currently Amended) The ~~therapeutic agent for depression~~ kit according to claim 20, wherein the antidepressant drug is a tetracyclic antidepressant.

25. (Currently Amended) The ~~therapeutic agent for depression~~ kit according to claim 24, wherein the tetracyclic antidepressant is maprotiline hydrochloride, mianserin hydrochloride or setiptiline maleate.

26. (Currently Amended) The ~~therapeutic agent for depression kit~~
according to claim 20, wherein the antidepressant drug is a selective serotonin reuptake
inhibitor.

27. (Currently Amended) The ~~therapeutic agent for depression kit~~
according to claim 26, wherein the selective serotonin reuptake inhibitor is fluoxetine
hydrochloride, sertraline hydrochloride, paroxetine hydrochloride, paroxetine
hydrochloride hydrate, citalopram hydrobromide, fluvoxamine maleate, trazodone
hydrochloride or nefazodone hydrochloride.

28. (Currently Amended) The ~~therapeutic agent for depression kit~~
according to claim 20, wherein the antidepressant drug is a selective noradrenalin reuptake
inhibitor.

29. (Currently Amended) The ~~therapeutic agent for depression kit~~
according to claim 28, wherein the selective noradrenalin reuptake inhibitor is reboxetine
mesylate, mirtazapine, maprotiline hydrochloride, nortriptyline hydrochloride, amoxapine,
bupropion or bupropion hydrochloride.

30. The ~~therapeutic agent for depression~~ kit according to claim 20,
wherein the antidepressant drug is a serotonin-noradrenalin reuptake inhibitor.

31. (Currently Amended) The ~~therapeutic agent for depression~~ kit
according to claim 30, wherein the serotonin-noradrenalin reuptake inhibitor is milnacipran
hydrochloride, venlafaxine hydrochloride or duloxetine hydrochloride.

32. (Currently Amended) The ~~therapeutic agent for depression~~ kit
according to claim 20, wherein the antidepressant drug is a dopamine reuptake inhibitor.

33. (Currently Amended) The ~~therapeutic agent for depression~~ kit
according to claim 32, wherein the dopamine reuptake inhibitor is venlafaxine
hydrochloride.


34. (Currently Amended) The ~~therapeutic agent for depression~~ kit
according to claim 20, wherein the antidepressant drug is a monoamine oxidase inhibitor.

35. The ~~therapeutic agent for depression~~ kit according to claim 34, wherein the monoamine oxidase inhibitor is selegiline hydrochloride, safinamide mesylate or moclobemide.

36. (Currently Amended) The ~~therapeutic agent for depression~~ kit according to claim 20, wherein the antidepressant drug is a 5-HT₂ antagonist.

37. (Currently Amended) The ~~therapeutic agent for depression~~ kit according to claim 36, wherein the 5-HT₂ antagonist is mirtazapine, trazodone hydrochloride or nefazodone hydrochloride.

38. (Currently Amended) (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione represented by the formula (I):




or a pharmaceutically acceptable salt thereof

~~for administering simultaneously or separately at a time interval in combination with an antidepressant drug.~~

Claims 39-40 (Cancelled).

41. (Currently Amended) A method for treating depression, which comprises administering to a patient in need thereof

(a) (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7- dihydro-1H-purine-2,6-dione represented by the formula (I):



or a pharmaceutically acceptable salt thereof and

(b) an antidepressant drug

simultaneously or separately at a time interval.

42. (Currently Amended) A pharmaceutical composition which comprises

(a) a compound having an adenosine A_{2A} receptor antagonistic activity or a pharmaceutically acceptable salt thereof and thereof:

(b) a monoamine oxidase inhibitor; and

(c) a pharmaceutically acceptable carrier.

Claims 43-45 (Cancelled).

46. (Original) A kit which comprises

- (a) a first component comprising a compound having an adenosine A_{2A} receptor antagonistic activity or a pharmaceutically acceptable salt thereof and
- (b) a second component comprising a monoamine oxidase inhibitor.

Claim 47 (Cancelled).

48. (Currently Amended) A method for treating depression, which comprises administering to a patient in need thereof

- (a) a compound having an adenosine A_{2A} receptor antagonistic activity or a pharmaceutically acceptable salt thereof and
 - (b) a monoamine oxidase inhibitor
- simultaneously or separately at a time interval.

Claims 49-50 (Cancelled).